Matsuo, Hiroshi
Ishikawa, Eiji http://orcid.org/0000-0001-7092-3650
Machida, Hirofumi
Mizutani, Yasuhide
Tanoue, Akiko
Ohnishi, Takahiro
Murata, Tomohiro
Okamoto, Shinya
Ogura, Toru
Nishimura, Yuki
Ito, Hiroo
Yasutomi, Masashi
Katayama, Kan
Nomura, Shinsuke
Ito, Masaaki
Funding for this research was provided by:
Sanwa Kagaku Kenkyusho CO., LTD. (No)
Article History
Received: 15 April 2019
Accepted: 29 November 2019
First Online: 16 December 2019
Compliance with ethical standards
:
: The MIE-CKD study was sponsored by Sanwa Kagaku Kenkyusho CO., LTD., which had no role in the data collection or analysis, decision to publish, or preparation of the manuscript. S.N. received lecture fees of more than 500,000 yen from Otsuka Pharma Inc. in 2016. M.I received lecture fees of more than 500,000 yen from Bayer Yakuhin, Ltd., Daiichi Sankyo Co. Ltd. and Mitsubishi Tanabe Pharma Corporation in 2016. The Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, was supported in part by unrestricted research grants of more than 1,000,000 yen from Daiichi Sankyo Co. Ltd., Shionogi & Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., MSD K.K., Astellas Pharma Inc., Takeda Pharmaceutical Company Limited and Pfizer Japan Inc. in 2016. The Division of Hemodialysis Center, Mie University Hospital, was supported in part by unrestricted research grants of more than 1,000,000 yen from Sanwa Kagaku Kenkyusho Co., Ltd., in 2016. No relevant conflicts of interest related to the article were disclosed by the authors.
: The protocol was initially approved by the Medical Research Ethics Review Committee of Mie University Hospital (reference number 2778) and subsequently by the institutional review boards at all other participating hospitals in accordance with the Declaration of Helsinki. This study was registered in the UMIN Clinical Trials Registry (registration ID number: UMIN000016172).
: Written informed consent was obtained from all patients before enrolment.